forecast glp-1 prescriptions growth 2025 semaglutide tirzepatide Receptor Agonist Market Report, 2033 Monitoring Report: GLP-1 RA Prescribing

According to our latest data, 44% of UK users have a new go-to retailer for groceries and household essentials, she says

The FDA does not approve compounded versions of semaglutide or tirzepatide and has issued warnings about them in 2026

acylation to extend half-life, modifications to improve receptor selectivity or bias, PEGylation) are used to improve pharmacokinetics, dosing interval, and tolerability

It promotes overall wellness, which aligns with our commitment to holistic health care

What are common side effects clinicians should watch for

Aim for at least 150 minutes of moderate-intensity exercise for good health